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2 
Abstract 1 
Objective:  Female C57BL6 mice exhibit less severe chondropathy compared with male mice. This 2 
paper tests the robustness of this observation and explores potential underlying mechanisms.  3 
Methods: OA was induced in male and female C57BL6 or DBA1 mice (n=6-12 per group) using 4 
destabilisation of the medial meniscus (DMM), or partial meniscectomy (PMX). Some mice were 5 
ovariectomised (OVX) (n=30). In vivo repair was assessed by focal cartilage defect or by joint 6 
immobilisation (sciatic neurectomy) after DMM. Histology, gene expression of whole knees, 7 
behavioural analysis using Laboratory Animal Behavior Observation Registration and Analysis 8 
System (LABORAS), and by Linton incapacitance, were used (n=7-10/group).  9 
Results:  Female mice displayed less severe chondropathy (20-75% reduction) across both strains, 10 
and after both surgeries. Activity levels 10 weeks after PMX were similar between males and females. 11 
Some repair-associated genes were increased in female joints after surgery but in vivo, no repair 12 
differences were evident. Despite having reduced chondropathy, females developed pain-like 13 
behaviour at the same time as male animals. At established pain-like behaviour (10 weeks post 14 
PMX), females differentially upregulated pain-associated genes including glial cell derived 15 
neurotrophic factor, neurturin, and neurotrophic factors 3 and 5. Inflammatory genes were not 16 
regulated in painful joints in either sex. 17 
Conclusion: We confirm strong structural joint protection in female mice which is not due to activity or 18 
intrinsic repair differences. Female mice develop pain at the same time as males,when a distinct set 19 
of neurotrophins are induced. We speculate that heightened pain sensitivity in females protects the 20 
joint by preventing overuse.   21 
 
 
3 
Introduction  22 
Epidemiological studies identify female sex as a major non-modifiable risk factor in OA development1. 23 
Sex-dependent associated risk holds true across different joint sites and at different ages and is 24 
particularly apparent after 55 years of age2-4. In the hand, the sex bias is particularly striking; 90% of 25 
those attending secondary care are female and the incidence peaks around the perimenopausal 26 
period1,3. The burden of hand OA in women increases as those individuals age2 tending to plateau at 27 
around the age of 80 (as does male disease)3,5. Males have significantly higher cartilage volume at all 28 
sites compared with females, even after accounting for differences in height, bone size and weight. 29 
This difference becomes more apparent after the age of 506. The sex bias in OA incidence and 30 
prevalence, particularly after 55 years of age, suggests an association with sex hormones and their 31 
changes at the time of the menopause. Despite the speculation that hormone replacement could 32 
protect female joints from OA, a systematic review of epidemiological studies has failed to support a 33 
joint-protective role of oestrogen in OA7. 34 
OA risk is also sex-dependent in mice. Young female mice subjected to destabilisation of the medial 35 
meniscus (DMM) develop less severe OA than male mice8. In this study, female mice that had been 36 
ovariectomised (OVX) (at 6 weeks of age) had significantly more severe OA than non-ovariectomised 37 
female mice. Conversely, orchidectomy (castration) in male mice reduced disease severity compared 38 
with non-operated males3,8. Similar studies have been performed in a number of different species3, 9, 39 
and a systematic review comparing the severity of OA after OVX concluded that OVX led to worse 40 
disease compared with non-ovariectomised females in around two thirds of cases10. The effects of 41 
exogenous oestrogen treatment are less conclusive. Only half of the studies looking at the effects of 42 
oestrogen replacement found reduced OA severity, and one study found exacerbation of disease10. 43 
Lack of conclusive results in these studies may be due to a failure to appreciate the complexity of the 44 
effects of multiple hormones affecting joint tissues, as well as inconsistency in study design and 45 
power. In animals as well as humans, ovariectomy affects the expression of several hormones 46 
besides oestrogen including decreases in progesterone and testosterone, and increases in follicle-47 
stimulating hormone (FSH) and luteinising hormone (LH)10. Receptors for oestrogen, androgens and 48 
FSH have been described in joint cells, including articular chondrocytes, and have been shown to 49 
affect tissue metabolism10-12.  50 
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If one regards OA as a disease of failed tissue repair, information may be gleaned from sex-51 
dependent wound responses in other tissues. Several other tissues exhibit sex differences in their 52 
response to injury. One that has been extensively examined is cutaneous wound healing. Ageing of 53 
healthy human skin is associated with reduced levels of transforming growth factor beta (TGFß)-1, 54 
reduced rate of cutaneous wound healing, albeit with reduced scarring. This age-related pattern can 55 
be reversed by systemic oestrogen therapy13. Similar relationships can be demonstrated in mice. 56 
Young female mice have significantly higher levels of Tgfß-1 than young males, and exhibit an 57 
increased inflammatory response to injury13. Ovariectomised females demonstrate delayed repair of 58 
incisional wounds which can be reversed by topical application of oestrogen, which was associated 59 
with increased latent Tgfß-1 secretion by dermal fibroblasts13. Orchidectomised mice display 60 
accelerated wound healing compared with non-castrated controls14.  61 
There are also sex differences in the perception of pain. Females patients present with more chronic 62 
pain conditions than males, and are known to experience higher levels of pain and have a lower 63 
threshold for pain15-18. The actual mechanisms of these sex differences is as yet unclear17. Females 64 
have been suggested to employ different immune cells in their responses to pain19,20. For example, in 65 
mice, females but not males, used adaptive immune cells within the spinal cord in the development of 66 
mechanical hypersensitivity21.  67 
In this paper we explore sex differences in murine OA in detail with a particular focus on the 68 
mechanisms that may drive differences in disease severity. We examine the impact on activity levels, 69 
ability to repair cartilage, molecular response to injury, and pain-like behaviour. 70 
 71 
Methods 72 
Animals and surgical methods are described in 22,23 with further details presented in Supplementary 73 
Methods. 74 
Sciatic Neurectomy: Animals were placed under general anaesthesia by inhalation of isoflurane 75 
(Vetpharma, Leeds, UK); 3% induction, 1.5-2% maintenance in 1.5-2 L/min O2. Hindlimbs were 76 
shaved and prepared for aseptic surgery. 0.3 mg/ml buprenorphine (Vetergesic Alstoe Animal Health, 77 
UK) was administered subcutaneously to all animals for analgesic purposes. The hindlimbs were 78 
stretched out and secured using surgical tape. From the midline, around 0.5cm lateral to the tail, a 79 
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1cm incision was made and the fascia and hind leg muscles separated. The sciatic nerve was 80 
exposed, lifted from the limb and a 2-4mm segment of the nerve was removed, causing minimal 81 
damage to the surrounding muscle, before the skin was closed and sutured.  82 
Focal Cartilage Injury: 10 week old male and female C57BL6 mice underwent focal cartilage injury in 83 
the patellar groove as previously described24. 8 weeks after injury, joints were scored using the 84 
previously described modified Pineda score25 to assess intrinsic cartilage repair. 85 
 86 
Histology: Mice were sacrificed by CO2 inhalation and the ipsilateral knee joints were collected for 87 
histological analyses by sharp division at the proximal femur and distal tibia. The skin and surrounding 88 
tissue were removed and joints subsequently fixed in 10% formalin for 24 hours before decalcification 89 
in 20% formic acid for one week. The tissue was paraffin-embedded and coronal sections of 4 90 
microns were cut at 80 micron intervals. Tissue slides were stained using Safranin-O and in the case 91 
of the PMX histology also FastGreen for microscopic inspection and histological scoring. Histological 92 
analysis of the knees was done by blinded scoring by two observers following the Osteoarthritis 93 
Research Society International (OARSI) scoring system26. Each joint consisted of eight to twelve 94 
scored sections. Each quadrant surface (lateral femoral condyle and tibial plateau and medial femoral 95 
condyle and tibial plateau) within the joint was scored separately, and the score from each histological 96 
section was added up to provide a section score. The three highest section scores obtained for any 97 
given joint were summed to yield a cartilage damage index for that animal.  98 
 99 
Osteophyte scoring: This was assessed either by histological grading of size and maturity according 100 
to previously validated methods27 or by micro-CT (ipsilateral and contralateral joints) as previously 101 
described by our group28. 102 
 103 
RNA extraction and reverse transcription–polymerase chain reaction (RT-PCR): RNA was extracted 104 
from whole knee joints, as described previously29. Briefly, after skin and muscle were removed the 105 
joint was trimmed to the upper and lower edges of the parapatellar and quadriceps tendon then snap 106 
frozen in liquid nitrogen. Whole knees were freeze-fractured using a pre-cooled bio-pulveriser. RNA 107 
from the powdered sample was isolated using RNeasy RNA mini kits (RNeasy mini kit, Qiagen, 108 
Hilden, Germany) according to the manufacturer’s instructions, then stored at -80°C. Samples were 109 
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reverse transcribed into cDNA using a high capacity RNA to cDNA kit (Applied Biosystems, CA, 110 
USA). Murine cDNA was analysed on two custom-made microfluidic cards (Taqman, Thermo 111 
Scientific) including hydrolysis probes, testing a total of 67 OA-related or pain-regulating genes (see 112 
Supplementary Table 1). Fold change was calculated using the 2-∆∆Ct method, where each gene of 113 
interest was compared to a housekeeper gene (either Fibroblast growth factor receptor 3, Fgfr3, or 114 
Glyceraldehyde 3-phosphate dehydrogenase, Gapdh) and normalised to the respective control group 115 
(naïve or sham) for each sex.  116 
Weight bearing: Static weight bearing measurements were performed using the Linton Incapacitance 117 
Tester (Linton Instrumentation, Norfolk, UK), as previously described30, 31. Briefly, mice were first 118 
acclimatised to the chamber on two separate occasions over two weeks before experimental 119 
measurements. Mice were manoeuvred inside the chamber to stand with one hindlimb on each 120 
weighing scale. The weight placed on each hindlimb was measured over a one second interval for at 121 
least three consecutive measurements. Results were expressed as the percentage of weight 122 
transmitted through the operated compared with the contralateral limb. One female observer each 123 
(I.v.L. for PMX, C.D. for DMM experiments) performed the measurements and was blinded to the 124 
treatment status of the mice. 125 
LABORAS: Laboratory Animal Behavior Observation Registration and Analysis System (LABORAS) 126 
allows for the measurement of mouse activity in an undisturbed environment overnight. Mice were 127 
housed singly, with 4 cages in use at any one time. They were given food and water ad libitum. Cages 128 
contained sawdust bedding but no additional enrichment. LABORAS picked up vibrations of animal 129 
movement and converted these into behaviour classifications, specifically "climbing", "locomotion", 130 
"inactivity", "rearing", "grooming", "drinking", and "eating". Measurements were performed during the 131 
mouse’s 12h active period (excluding the initial exploratory phase) 19:00-07:00.  Total duration for 132 
each activity over the 12 hours was calculated. 133 
 134 
Statistical analyses: Data are expressed as mean ± standard error of the mean (SEM) and were 135 
analysed using GraphPad Prism (GraphPad Software, San Diego, CA). For behavioural comparisons 136 
of two groups only a t-test with Bonferroni multiple comparisons test, where applicable, was used. For 137 
behavioural comparisons of three groups and without a repeated-measures timecourse, an ordinary 138 
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two-way ANOVA with Tukey multiple comparisons test was applied. For any timecourse experiments, 139 
a repeated-measures two-way ANOVA with a Bonferroni test for multiple comparisons was used. In 140 
case of missing timepoints, a mixed model with a Bonferroni multiple comparisons test was used 141 
instead of a repeated-measures two-way ANOVA. 142 
 143 
Results 144 
Do female mice develop lower chondropathy scores after surgical joint destabilisation?  145 
We examined sex differences in chondropathy score after joint destabilisation in a number of different 146 
groups, specifically asking whether sex differences were robust (1) after different types of surgery 147 
(DMM or PMX), and (2) across different genetic strains (C57BL6 or DBA). Lower disease severity in 148 
female mice was apparent following both DMM and PMX surgery from 8 weeks (DMM) and 12 weeks 149 
(PMX) (Figure 1A, B, C). Following PMX, disease severity plateaued in both female and male mice 12 150 
weeks after PMX. OVX females did not have different disease scores following PMX compared with 151 
female controls at any timepoint examined. In another strain, female DBA1 mice also displayed 152 
reduced chondropathy after DMM compared with males (Figure 1D). Osteophyte volume and maturity 153 
was also assessed (Figure 1E, F). This was measured by histology and by micro-CT, using the 154 
epiphyseal volume as a surrogate marker for osteophyte size according to our validated method28. 155 
Osteophyte maturity was similar between male and female mice. Osteophytes were smaller in female 156 
mice than males, but as a proportion of the total volume of the epiphysis, this represented the same 157 
percentage increase (Figure 1G, H).  158 
 159 
Are female mice less active than male mice? 160 
One possible explanation for the decreased disease observed in female mice was reduced joint use 161 
through reduced activity. We assessed activity levels of males and females using LABORAS over a 162 
12-hour period. LABORAS allows the recording of different behavioural activities of single-caged 163 
animals. It is able to distinguish between ‘climbing’, ‘locomotion’, ‘immobility’, ‘grooming’, ‘drinking’, 164 
and ‘eating’. When comparing the mean activity over the 12h period 10 weeks after PMX, there were 165 
no significant differences between sham and PMX groups for either sex, and no apparent differences 166 
between sexes. This was the case when considering the total activity over 12 hours or after breaking 167 
activity levels down to one-hour periods (data not shown). (Figure 2). Similar activity levels were seen 168 
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in naïve (non-surgery) male and female mice (data not shown). The full male data set will be 169 
published elsewhere (manuscript in revision). These data indicate that LABORAS is not a sensitive 170 
tool for detecting pain-like behaviour, but do not support that differences in activity levels account for 171 
differences in structural joint damage.  172 
Do female mice repair cartilage better than male mice? 173 
We next tested the hypothesis that female mice are more able to repair damaged cartilage than male 174 
mice and this could account for reduced chondropathy scores. We first assessed gene expression in 175 
response to acute joint destabilisation by extracting RNA from the whole knee joint 6 hours after 176 
DMM. The analysis focused on pathways implicated in cartilage repair including fibroblast growth 177 
factors (FGF) (FGF2, FGF18, FGFR1-2,4) and TGFß (TGFß1-3, TGFßR2-3). Pmepa1, Bmpr2 and 178 
Ltbp2 had previously been shown by our group to be strong TGFß-dependent genes in human 179 
chondrocytes33 (Table 1). Several genes were only upregulated in female joints and three were 180 
significantly higher in female compared with male mice: Bmpr2, Fgf2, and Pmepa1. Another TGFß 181 
family member that is strongly induced by FGF2, Inhibin A (Inhba) (the homodimer of which forms 182 
activin A) was upregulated equally in both male (5.92 ± 1.14, p<0.01) and female joints (6.33 ± 0.60, 183 
p<0.0001).  184 
Gene expression data suggested that the response to joint injury may produce a stronger anabolic 185 
response in female compared with male mice. We investigated whether this related to improved repair 186 
of articular cartilage after injury in vivo. Previously published data from our lab showed that OA 187 
development could be prevented by performing joint immobilisation by sciatic neurectomy at the time 188 
of joint destabilisation29. Others have previously demonstrated that joint immobilization facilitated joint 189 
repair after injury34, 35. To test whether female mice exhibited enhanced cartilage repair in vivo, we 190 
used two different models. In the first we used a focal cartilage defect model originally described by 191 
Eltawil and colleagues24. In this model, which had historically been tested in male mice only, the 192 
authors showed both an age and strain dependent influence on repair with only young DBA1 mice 193 
exhibiting repair of the focal defect24.  194 
Male and female C57BL6 mice underwent focal cartilage injury at 10 weeks of age in order to see 195 
whether females were more likely than males to repair their cartilage. Joints were examined 8 weeks 196 
later. Cartilage repair was assessed by a modified Pineda score25 (Figure 3A, B). No differences in 197 
repair were observed between the two groups. In a second model, we assessed whether joint 198 
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immobilisation by sciatic neurectomy, after disease was established, would allow reversal (repair) of 199 
cartilage damage induced by DMM surgery. This model has not been previously validated and we 200 
selected different timepoints for both male and female mice to ensure that there was a sufficient level 201 
of chondropathy at the start of the experiment. In both male and female mice neurectomy was able to 202 
arrest disease progression, but did not reverse disease (Figure 3C, D). Collectively, these data 203 
suggest that despite having a more “repair-conducive” molecular response to joint destabilisation, 204 
male and female C57BL6 mice both fail to exhibit functional repair in vivo.  205 
 206 
Do male mice mount a more catabolic response upon joint destabilisation? 207 
As the inflammatory response to injury has been shown to be sex-dependent in other tissues, we next 208 
addressed whether there was a difference in inflammatory gene regulation between sexes that could 209 
account for a more catabolic response in male joints. We assessed genes associated with the 210 
inflammatory response in both males and females 6 hours after DMM in the whole knee joint 211 
compared with naive mice of each sex (Table 1). Inflammatory genes were upregulated to a similar 212 
extent in both male and female joints. MMP-19 was the only gene that was significantly different 213 
between sexes (higher in females than males; 4.45 ± 0.56, 2.46 ± 0.29 respectively) (p<0.05). Based 214 
on these early 6-hour results, we concluded that differences in the inflammatory response to injury 215 
was unlikely to explain the sex differences seen in chondropathy.  216 
 217 
Do male and female mice display different OA pain-like behaviour? 218 
We next tested whether females displayed different pain-like behaviours to male mice. We assessed 219 
spontaneous pain-like behaviour after sham or OA surgery (DMM or PMX) in male, female, and OVX 220 
(PMX only) mice using Linton incapacitance testing, which measures weight asymmetry through the 221 
hind limbs. Spontaneous pain-like behaviour was seen transiently in the post-operative period in all 222 
groups and then from around 9 weeks after PMX and 10 weeks after DMM (Figure 4A, B). No 223 
difference in the timing or severity could be discerned between the sexes. These results were 224 
somewhat surprising as we had previously concluded that chondropathy score predicted time of onset 225 
of late OA pain-like behaviour in male mice36,37 through release of pain sensitising molecules such as 226 
nerve growth factor (NGF) from the damaged articular cartilage36. These results suggested that 227 
females either have an exaggerated  behavioural response to modest cartilage damage or that 228 
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additional pain sensitising pathways are activated, perhaps elsewhere in the joint, that were 229 
independent of cartilage loss. To test these hypotheses further, we assessed the differences in joint 230 
molecular profile at the time of established OA pain-like behaviour (10 weeks after PMX). 231 
 232 
Is the molecular pain response different between male and female mice? 233 
To assess sex differences in the regulation of genes associated with pain, we assessed a panel of 234 
pain-related genes that we had previously used as a screening tool at a time of established late OA 235 
pain36. This list included 29 genes that were either associated with inflammation (cytokines, 236 
chemokines, and leukocyte activation markers) or were known pain sensitisers. We compared the 237 
expression of these molecules in whole knee joints between sexes, 10 weeks after PMX surgery 238 
(when pain-like behaviour was established) (Table 2). No statistically significant regulation in 239 
inflammatory genes was seen in either group, in keeping with our previously published data, and 240 
suggesting that inflammatory changes in the joint are not a major driver of pain-like behaviour at this 241 
time36. Il15 and Nos2 were relatively higher in females (Il15 1.51 ± 0.23, Nos2 1.32 ± 0.14) when 242 
compared with males (Il15 0.75 ± 0.13, Nos2 0.85 ± 0.09, p<0.05) although neither were upregulated 243 
significantly above the respective sham control. In contrast, when considering the pain sensitising 244 
molecules, significant sex-dependent changes were observed. Male mice showed significant 245 
increases in Ngf (1.76 ± 0.14, p<0.01) and Bdkrb1 (2.48 ± 0.34, p<0.05) in keeping with our previous 246 
publication36. Females, had strong and significant upregulation of a group of neurotrophins including 247 
Gdnf (2.54 ± 0.30) and Nrtn (6.71 ± 1.24) when compared with their respective sham or male PMX 248 
control. A further two neurotrophins Ntf3 (1.92 ± 0.27), and Ntf5 (2.89 ± 0.48) were upregulated 249 
compared with males (p<0.05, p<0.001 respectively), but not significantly compared with their sham 250 
control. Pspn was downregulated in females (0.40 ± 0.12) compared with males (1.19 ± 0.27, p<0.05). 251 
Raw CT values are shown for both the inflammatory and pain-related molecules in the sham operated 252 
and OA groups in Supplementary Table 2. No significant differences between sexes in sham basal 253 
activity in any of these genes was detected (by t test, data not shown). Collectively these results 254 
suggest that females develop pain-like behaviour after less severe cartilage damage and may use 255 
different molecular pathways to drive pain-like behaviour.   256 
 257 
Discussion 258 
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We have confirmed a previous report showing that male mice develop more severe 259 
chondropathy after surgical joint destabilisation compared with females8 and extended the previous 260 
study by showing that this was robust across different strains and surgical induction methods. We 261 
were unable to confirm a reversal of female protection in OVX animals. This is not easily explained 262 
but it is the case that several other studies have failed to observe this also10. OVX mice were 263 
purchased from a commercial provider and we were able to verify oestrogen deficiency by oestrogen 264 
dependent gene expression (data not shown). The previously published Ma et al. study concluded by 265 
suggesting that lower chondropathy might be due to different activity levels between males and 266 
females (higher activity predisposing to increased disease). We were unable to substantiate this using 267 
LABORAS. We did not find evidence of different activity levels between the two sexes, although we 268 
were also unable to distinguish activity levels between PMX and sham operated animals in either sex 269 
indicating that LABORAS is not very sensitive. Further details of this insensitivity will be published 270 
elsewhere (manuscript in revision). 271 
Next, we explored sex differences in the molecular response to joint destabilisation, 272 
addressing specific clusters of disease modifying genes. Looking at the immediate post injury gene 273 
expression profile in whole knee joints, we saw no difference in the inflammatory/catabolic genes 274 
between male and female mice but did see some differences in genes relating to the TGFß pathway, 275 
suggesting that females could elicit an enhanced repair response after injury. This was subsequently 276 
tested in two models of in vivo repair. No differences between the sexes were observed and we 277 
concluded that their repair profile (or lack thereof), at least in these stringent models, was similar.  278 
Interestingly, we found the same time of onset and severity of pain-like behaviour in male and 279 
female mice following either DMM or PMX. This has recently been confirmed by another group 280 
following the medial meniscal transection model (MMT) in which the authors also confirm reduced 281 
chondropathy in female mice38. This was a little surprising in view of the fact we had previously 282 
suggested that the onset of pain-like behaviour in mice arises at the time that the junction between 283 
the calcified and non-calcified cartilage (tidemark) is breached36. These results could have suggested 284 
that pain-like behaviour in female mice was originating from a tissue other than the cartilage, such as 285 
the synovium. Although we can’t completely exclude this possibility, the inflammatory gene profile in 286 
the joint at the onset of pain-like behaviour indicated that there was little joint inflammation present in 287 
either male or female OA joints suggesting that synovitis was unlikely to be contributing to the pain 288 
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phenotype. This suggests that female OA pain-like behaviour in this model is ‘non-inflammatory’ as 289 
we have concluded previously in males36. We also studied osteophyte development in male and 290 
female joints. Osteophyte development in murine OA occurs rapidly after joint destabilisation (within 291 
the first two weeks)28 and does not correlate temporally with pain-like behaviour changes. No 292 
differences in the size (by % volume of the ephiphysis) or maturity of the osteophyte were detected 293 
between male and female mice. 294 
At the time of established OA pain-like behaviour, it appears that female mice regulate a 295 
different, additional set of potential pain-modulating genes. These included Gdnf , Nrtn , Ntf3 , Ntf5  296 
and Pspn . GDNF, NRTN and PSPN are trophic factors for dopaminergic motoneurons and midbrain 297 
neurons and are being explored in Parkinson’s disease39,40. They signal through a common receptor 298 
family and are all part of the TGFβ superfamily41. GDNF and NRTN and have been associated with 299 
inflammatory bone pain42, and GDNF has also been suggested as an analgesic target in neuropathic 300 
pain39,40. As we found that TGFß activity was increased in females after joint injury compared with 301 
males, it is possible that a common mechanism exists for the activation of TGFβ superfamily 302 
molecules. NTF3 and NTF5 are both neurotrophic factors related to NGF. NTF3 and NTF5 are largely 303 
regarded as a survival factors for sensory neurons43,44, but NTF3 has also been shown to have 304 
analgesic effects specifically by down-regulating TRPV1 and suppressing thermal hyperalgesia45. No 305 
sex differences have been reported for the regulation of any of these molecules. NGF, a well-known 306 
pain target for OA46,47, was not differentially regulated between the sexes, suggesting that it 307 
contributes to OA pain-like behaviour in both male and female mice, although in this analysis NGF 308 
was not significantly increased in female joints above sham-operated joints. It would have been nice 309 
to check that both male and female mice responded equally to anti-NGF therapy, but this was not 310 
available to us.  311 
Our data are consistent with mounting evidence that shows pain can be relayed by different 312 
mechanisms in males and females, suggesting that there are common as well as distinct sex-specific 313 
pathways48. Females have been shown to employ cells of the adaptive immune system to relay pain-314 
like behaviour21. Although we can’t completely exclude a mechanism that involves adaptive immune 315 
cells in the present study, we did not see any evidence of classical inflammatory gene regulation in 316 
either male or female joints at the time the mice developed pain-like behaviour.  317 
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The inclusion of women in clinical studies has only become mandatory in the US in 1993, 318 
whilst preclinical studies still do not require the inclusion of both sexes17,49. Part of this is due to fear of 319 
oestrous cycle-related variability in females, although it has been suggested that fighting to establish 320 
dominance hierarchies in male mice can introduce as much variability, if not more17. The inclusion of 321 
females in preclinical studies is important to identify female-specific pathways in drug discovery and to 322 
avoid results from male animals being falsely generalised to females17,49. The marked female 323 
predominance in chronic pain conditions; higher documented pain sensitivity, lower pain thresholds, 324 
and higher pain ratings15-18 reinforces the fact that preclinical studies probably need to be done in both 325 
sexes if we are to attempt to understand their molecular basis. This approach is already being 326 
implemented by the NIH in the US50. This work has important implications for NC3Rs. Whilst the goals 327 
of replacement, reduction, and refinement must be upheld, it may be necessary to study such 328 
pathways in both sexes in order not to miss sex-specific differences. What is also evident is that it 329 
would not be appropriate to perform analyses of mixed populations of male and female animals in 330 
mechanistic studies. 331 
Finally, could chondroprotection in female mice be as a result of earlier pain sensitisation? 332 
Given the highly mechanosensitive nature of OA29, we speculate, as others have done previously, 333 
that pain protects the joint by preventing overuse. As female mice are sensitized at an earlier stage of 334 
their disease this could be one mechanism to explain the reduced chondropathy observed. This 335 
debate is topical in view of the discussion around rapidly progressive OA in individuals receiving good 336 
analgesic control with therapies such as anti-NGF51. 337 
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Figure Legends: 
Figure 1: Reduced chondropathy scores in female mice following joint destabilisation. OARSI 462 
scores of ipsilateral joints after DMM surgery in male and female C57BL6 mice (A). OARSI scores 463 
after PMX in male, female and OVX female mice (B). The male data of weeks 8 and 12 has 464 
previously been published as a supplementary figure32. Representative histological sections of the 465 
medial compartment of the joint (C) from histological scores in (B). OARSI scores after DMM surgery 466 
in male and female DBA1 mice (D). Osteophyte size (E) or maturity (F) by histology. Osteophyte size 467 
by micro-CT shown as total epiphyseal volume of right (R) (operated) and left (L) (non-operated) 468 
epiphyses (G), or expressed as the % increase over the unoperated side (H). SEM shown. (A, B, D) 469 
Two-way ANOVA or, in the absence of the same sample size within a timepoint, mixed effect analysis 470 
with Bonferroni post hoc for multiple testing. Asterisks indicate un-paired t-test (E-F), and paired t-test 471 
(G-H). Only significant differences shown *p<0.05, ***p<0.001, ****p<0.0001 comparing male with 472 
females in all cases except in (G). 473 
Figure 2: Activity differences in male and female C57BL6 mice 10 weeks after PMX or sham 474 
surgery. Male and female mice, 10 weeks after PMX surgery, were singly housed in LABORAS 475 
recording cages for 18h overnight (15:00 - 9:00) (n=7-10/group) with analysis performed between 476 
19:00 and 07:00. No significant differences were observed between PMX and sham groups in either 477 
males or females. Activity levels were similar between sexes. One-way ANOVA with Bonferroni post 478 
hoc for multiple testing. SEM shown. 479 
 480 
Figure 3: Female mice do not exhibit enhanced cartilage repair compared with male mice. 481 
Cartilage repair scores 8 weeks after focal cartilage injury of the intercondylar groove (A) with 482 
representative images at 0 and 8 weeks after injury (B). No significant differences were observed 483 
between groups. OARSI scores of joints of male mice following either DMM alone or DMM followed 484 
by joint immobilisation (by sciatic neurectomy, ScN) at either 4 or 8 weeks post DMM (C). OARSI 485 
scores of joints of female mice following DMM alone, or DMM followed by joint immobilisation (by 486 
sciatic neurectomy, ScN) at 12 weeks (D). For both males and females, Joint immobilisation halted 487 
disease progression. Ordinary one-way ANOVA with Tukey post hoc for multiple comparisons. SEM 488 
shown.  489 
 490 
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Figure 4: Male and female mice exhibit similar pain-like behaviours after either DMM or PMX. 491 
Pain-like behaviour was tested in male and female mice by Linton incapacitance at a variety of times 492 
after surgical induction of OA by DMM (A) or PMX (B). Significant differences shown compared with 493 
sham group by mixed effects analysis with a Dunnett post hoc for multiple comparisons (A) or 494 
repeated measures two-way ANOVA with Sidak post hoc for multiple comparisons (B). SEM shown. 495 
n=10 DMM, n=15 PMX, n=6 Shams, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  496 
Table 1: Average fold changes (FC) of expression of genes associated with repair and inflammation 497 
in the whole knee joints 6 hours after DMM surgery normalised and expressed relative to the 498 
respective naive control. Asterisks indicate unpaired t-tests within each sex, p-values compare 6-hour 499 
data across sexes by unpaired t-test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). SEM shown. 500 
Table 2: Average fold changes (FC) of expression of genes associated with inflammation and pain in 501 
the whole knee joints 10 weeks after PMX surgery normalised and expressed relative to the 502 
respective sham-operated group. Asterisks indicate unpaired t-tests within each sex, p-values 503 
compare 10-week PMX data across sexes by unpaired t-test (*p<0.05, **p<0.01,). SEM shown.504 
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Supplementary Table 1: Genes examined on TaqMan Low-Density Array (TLDA) microfluidic 505 
cards 506 
Supplementary Table 2: Average raw CT values (± SEM) of genes associated with inflammation 507 
and pain in whole knees 10 weeks after PMX or sham surgery 508 
509 
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 Genes 
Naive Male 
(normalised) 
6h DMM Male 
FC±SD  
Naive Female 
(normalised) 
6h DMM Female  
FC±SD 
Males vs Females 
6h DMM 
Repair 
Bmpr2 1.02 ± 0.10 1.04 ± 0.09  1.00 ± 0.01 1.52 ± 0.13** p<0.05 
Ctgf 1.03 ± 0.16 1.68 ± 0.17  1.01 ± 0.09 2.11 ± 0.39*   
Fgf18 1.04 ± 0.16 1.61 ± 0.21  1.00 ± 0.06 1.44 ± 0.07**   
Fgf2 1.04 ± 0.16 1.52 ± 0.32  1.01 ± 0.09 2.53 ± 0.03**** p<0.05 
Fgfr1 1.04 ± 0.18 1.05 ± 0.16  1.02 ± 0.12 1.30 ± 0.10    
Fgfr2 1.02 ± 0.13 0.95 ± 0.08  1.01 ± 0.07 0.87 ± 0.03    
Fgfr4 1.04 ± 0.14 0.64 ± 0.08  1.05 ± 0.18 1.41 ± 0.32    
Inhba 1.02 ± 0.12 5.92 ± 1.14** 1.01 ± 0.06 6.33 ± 0.60****   
Ltbp1 1.01 ± 0.09 1.05 ± 0.23  1.01 ± 0.10 0.97 ± 0.07    
Ltbp2 1.00 ± 0.05 0.97 ± 0.13  1.01 ± 0.09 1.25 ± 0.08    
Pmepa1 1.03 ± 0.16 1.37 ± 0.22  1.01 ± 0.09 2.46 ± 0.27*** p<0.05 
Tgfb1 1.03 ± 0.17 1.07 ± 0.10  1.02 ± 0.12 1.17 ± 0.08    
Tgfb2 1.02 ± 0.11 0.69 ± 0.08  1.01 ± 0.09 0.73 ± 0.05    
Tgfb3 1.00 ± 0.06 0.72 ± 0.06  1.02 ± 0.14 1.00 ± 0.26    
Tgfbr1 1.02 ± 0.10 1.20 ± 0.20  1.00 ± 0.05 1.20 ± 0.06    
Tgfbr2 1.07 ± 0.21 1.03 ± 0.10  1.02 ± 0.13 1.04 ± 0.07    
Tgfbr3 1.03 ± 0.16 0.86 ± 0.19  1.02 ± 0.12 1.30 ± 0.15    
Inflammatory 
Adamts1 1.03 ± 0.17 4.52 ± 1.06** 1.01 ± 0.07 6.65 ± 0.71****   
Adamts4 1.08 ± 0.24 6.75 ± 2.52* 1.01 ± 0.09 12.05 ± 1.11*   
Adamts5 1.05 ± 0.19 1.92 ± 0.55  1.01 ± 0.06 2.04 ± 0.20    
Arg1 1.11 ± 0.31 61.05 ± 24.71  7.35 ± 7.02 44.75 ± 6.55***   
Ccr2 1.04 ± 0.18 1.03 ± 0.16  1.00 ± 0.05 1.67 ± 0.25    
Cd68 1.05 ± 0.19 1.17 ± 0.15  1.02 ± 0.12 1.13 ± 0.02    
Il1a 1.14 ± 0.33 0.95 ± 0.23  1.07 ± 0.24 1.08 ± 0.22    
Il1b 1.04 ± 0.16 6.29 ± 1.23** 1.01 ± 0.06 6.31 ± 0.40****   
Il6 1.20 ± 0.38 131.49 ± 49.15  1.00 ± 0.05 129.19 ± 24.35***   
Mmp13 1.05 ± 0.20 1.30 ± 0.23  1.01 ± 0.07 1.63 ± 0.10*   
Mmp19 1.02 ± 0.13 2.46 ± 0.29  1.01 ± 0.10 4.45 ± 0.56**** p<0.05 
Mmp3 1.00 ± 0.05 6.58 ± 1.48  1.03 ± 0.14 13.24 ± 2.64****   
Ptgs2 1.01 ± 0.09 24.51 ± 4.89  1.04 ± 0.15 20.16 ± 2.31**   
Timp1 1.07 ± 0.23 2.72 ± 0.77  1.03 ± 0.12 3.01 ± 0.27**   
Tnfaip6 1.03 ± 0.14 25.91 ± 6.52*** 1.12 ± 0.32 18.56 ± 2.15****   Naive Male 
(normalised) 
6h DMM Male 
FC±SD  
Naive Female 
(normalised) 
6h DMM Female 
FC±SD 
Males vs Females 
6h DMM 
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 GENE 
  
Male Sham 
wk10 
(normalised) 
Male PMX 
wk10 FC±SD  
Female Sham 
wk10 FC±SD 
(normalised) 
Female PMX 
wk10 FC±SD  
PMX Male vs 
Female  
Inflammatory 
Ccl19 1.04 ± 0.19 1.50 ± 0.35 1.01 ± 0.09 0.92 ± 0.06   
Ccl2 1.02 ± 0.14 1.21 ± 0.34 1.04 ± 0.20 1.06 ± 0.16   
Ccr2 1.01 ± 0.13 1.18 ± 0.28 1.07 ± 0.25 1.12 ± 0.11   
Ccr7 1.02 ± 0.15 0.99 ± 0.21 1.03 ± 0.17 1.23 ± 0.10   
Cd14 1.01 ± 0.08 1.45 ± 0.44 1.05 ± 0.24 1.10 ± 0.09   
Il10 1.11 ± 0.38 1.69 ± 0.68 1.05 ± 0.21 1.60 ± 0.19   
Il15 1.05 ± 0.25 0.75 ± 0.13 1.01 ± 0.11 1.51 ± 0.23 p<0.05 
Il1r1 1.01  ± 0.11 1.64  ± 0.18 1.02 ± 0.14 1.49 ± 0.15   
Il2 1.11  ± 0.37 0.99  ± 0.20 1.03 ± 0.16 1.48 ± 0.43   
Il4 1.01  ± 0.10 0.90  ± 0.31 1.02 ± 0.13 1.72 ± 0.21   
Il6 1.06  ± 0.28 0.88  ± 0.17 1.02 ± 0.15 1.30 ± 0.18   
Il6ra 1.06  ± 0.28 1.19  ± 0.20 1.01 ± 0.08 1.54 ± 0.21   
Nos2 1.02  ± 0.15 0.85  ± 0.09 1.03 ± 0.17 1.32 ± 0.14 p<0.05 
Tnf 1.00 ± 0.02 1.45 ± 0.17 1.09 ± 0.30 1.30 ± 0.09   
Pain          
Bdkrb1 1.01 ± 0.09 2.48 ± 0.34 * 1.09 ± 0.32 1.57 ± 0.23   
Bdkrb2 1.00 ± 0.04 1.60 ± 0.35 1.08 ± 0.32 1.20 ± 0.10   
Cnr1 1.01 ± 0.11 0.89 ± 0.19 1.09 ± 0.33 1.10 ± 0.14   
Cnr2 1.02 ± 0.13 1.35 ± 0.20 1.02 ± 0.16 1.26 ± 0.17   
Gal 1.02 ± 0.13 1.15 ± 0.28 1.00 ± 0.05 1.21 ± 0.13   
Gdnf 1.01 ± 0.08 0.95 ± 0.20 1.06 ± 0.22 2.54 ± 0.30 * p<0.01 
Ngf 1.01  ± 0.10 1.76  ± 0.14 ** 1.06 ± 0.26 1.56 ± 0.26   
Npy 1.03 ± 0.16 1.38 ± 0.48 1.08 ± 0.27 0.62 ± 0.08   
Nrtn 1.03 ± 0.19 1.07 ± 0.41 1.02 ± 0.15 6.71 ± 1.24 * p<0.01 
Ntf3 1.05 ± 0.24 1.03 ± 0.20 1.11 ± 0.37 1.92 ± 0.27 p<0.05 
Ntf5 1.04 ± 0.21 0.33 ± 0.12 * 1.02 ± 0.14 2.89 ± 0.48 p<0.001 
Penk 1.03 ± 0.18 1.19 ± 0.11 1.17 ± 0.46 1.16 ± 0.15   
Pspn 1.05 ± 0.23 1.19 ± 0.27 1.15 ± 0.44 0.40 ± 0.12 p<0.05 
Tac1 1.01 ± 0.10 1.15 ± 0.44 1.06 ± 0.26 1.43 ± 0.15   
Tacr1 1.01 ± 0.09 2.17 ± 0.53 1.43 ± 0.85 1.68 ± 0.27   
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Supplementary Table 1: Genes examined on TaqMan Low-Density Array (TLDA) microfluidic cards 
 
Gene with accession no. Comments 
Adamts1-
Mm00477355_m1 
a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 1 
Adamts4-
Mm00556068_m1 
a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 4 
Adamts5-
Mm00478620_m1 
a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 5 (aggrecanase-2) 
Arg1-Mm00475988_m1 arginase, liver 
Bdkrb1-Mm04207315_s1 bradykinin receptor, beta 1 
Bdkrb2-Mm00437788_s1 bradykinin receptor, beta 2 
Bmpr2-Mm00432134_m1 
bone morphogenetic protein receptor, type II (serine/threonine 
kinase) 
Ccl19-Mm00839967_g1 chemokine (C-C motif) ligand 19 
Ccl2-Mm00441242_m1 chemokine (C-C motif) ligand 2 
Ccr2-Mm01216173_m1 chemokine (C-C motif) receptor 2 
Ccr7-Mm01301785_m1 chemokine (C-C motif) receptor 7 
Cd14-Mm00438094_g1 CD14 antigen  
Cd68-Mm03047343_m1 CD68 antigen 
Cnr1-Mm00432621_s1 cannabinoid receptor 1 (brain) 
Cnr2-Mm00438286_m1 cannabinoid receptor 2 (macrophage) 
Ctgf-Mm01192932_g1 connective tissue growth factor 
Fgf18-Mm00433286_m1 fibroblast growth factor 18 
Fgf2-Mm00433287_m1 fibroblast growth factor 2 
Fgfr1-Mm00438930_m1 fibroblast growth factor receptor 1 
Fgfr2-Mm00438941_m1 fibroblast growth factor receptor 2 
Fgfr3-Mm00433294_m1 fibroblast growth factor receptor 3 
Fgfr4-Mm01341852_m1 fibroblast growth factor receptor 4 
Gal-Mm00439056_m1 galanin 
Gapdh-Mm99999915_g1 glyceraldehyde-3-phosphate dehydrogenase 
Gdnf-Mm00599849_m1 glial cell line derived neurotrophic factor 
Has1-Mm03048195_m1 hyaluronan synthase1 
Il10-Mm00439616_m1 interleukin 10 
Il15-Mm00434210_m1 interleukin 15 
Il1a-Mm00439620_m1 interleukin 1 alpha 
Il1b-Mm00434228_m1 interleukin 1 beta 
Il1r1-Mm00434237_m1 interleukin 1 receptor, type I 
Il2-Mm00434256_m1 interleukin 2 
Il4-Mm00445260_m1 interleukin 4 
Il6-Mm00446190_m1 interleukin 6 
Il6ra-Mm00439653_m1 interleukin 6 receptor, alpha 
Inhba-Mm00434339_m1 inhibin beta-A  
Ltbp1-Mm00498234_m1 latent transforming growth factor beta binding protein 1 
Ltbp2-Mm01307379_m1 latent transforming growth factor beta binding protein 2 
Mmp13-Mm00439491_m1 matrix metallopeptidase 13 
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Supplementary Table 2: Average raw CT values (± SEM) of genes associated with 
inflammation and pain in whole knees 10 weeks after PMX or sham surgery 
 
Gene  
M Sham Wk10 
CT±SEM  
M PMX Wk10 
CT±SEM  
F Sham Wk 10 
CT±SEM  
F PMX Wk 10 
CT±SEM  
Gapdh (control) 15.27 ± 0.15 15.55 ± 0.41 15.91 ± 0.30 15.92 ± 0.15 
Inflammatory 
Ccl19 26.60 
 
± 0.14 26.53 
 
± 0.82 26.34 
 
± 0.26 26.48 
 
± 0.11 
Ccl2 26.73 ± 0.08 27.06 ± 0.89 26.90 ± 0.08 26.88 ± 0.25 
Ccr2 21.51 ± 0.10 21.67 ± 0.51 22.26 ± 0.13 22.13 ± 0.12 
Ccr7 27.38 ± 0.10 27.86 ± 0.74 27.18 ± 0.10 26.91 ± 0.14 
Cd14 25.96 ± 0.12 25.92 ± 0.62 26.22 ± 0.14 26.11 ± 0.12 
Il10 29.11 ± 0.37 29.01 ± 0.74 29.19 ± 0.11 28.56 ± 0.21 
Il15 23.93 ± 0.24 24.77 ± 0.72 25.01 ± 0.15 24.49 ± 0.20 
Il1r1 24.91 ± 0.08 24.52 ± 0.50 25.24 ± 0.10 24.71 ± 0.23 
Il2 31.73 ± 0.46 32.15 ± 0.60 32.77 ± 0.11 32.45 ± 0.49 
Il4 28.07 ± 0.02 28.89 ± 0.86 29.22 ± 0.40 28.49 ± 0.10 
Il6 27.85 ± 0.26 28.47 ± 0.74 28.60 ± 0.30 28.28 ± 0.22 
Il6ra 24.22 ± 0.24 24.33 ± 0.57 24.63 ± 0.27 24.06 ± 0.08 
Nos2 30.61 ± 0.32 31.17 ± 0.42 31.85 ± 0.24 31.49 ± 0.14 
Tnf 25.66 ± 0.12 25.45 ± 0.44 25.92 ± 0.13 25.56 ± 0.09 
Pain 
Bdkrb1 30.48 
± 
0.09 29.52 
± 
0.63 30.34 
± 
0.12 29.75 
± 
0.32 
Bdkrb2 30.74 ± 0.16 30.48 ± 0.73 30.91 ± 0.17 30.68 ± 0.22 
Cnr1 28.65 ± 0.16 29.27 ± 0.76 29.09 ± 0.19 29.01 ± 0.05 
Cnr2 24.65 ± 0.10 24.59 ± 0.64 24.88 ± 0.09 24.61 ± 0.10 
Gal 29.63 ± 0.25 30.32 ± 1.30 30.07 ± 0.34 29.85 ± 0.11 
Gdnf 31.26 ± 0.22 31.86 ± 0.87 32.55 ± 0.64 31.25 ± 0.10 
Ngf 29.74 ± 0.02 29.23 ± 0.49 29.56 ± 0.10 29.00 ± 0.36 
Npy 28.03 ± 0.36 28.17 ± 0.75 27.61 ± 0.20 28.34 ± 0.12 
Nrtn 27.52 ± 0.19 27.61 ± 0.42 29.86 ± 0.50 27.24 ± 0.36 
Ntf3 27.28 ± 0.33 27.68 ± 0.74 28.04 ± 0.25 27.19 ± 0.30 
Ntf5 29.14 ± 0.28 31.45 ± 0.99 31.72 ± 0.50 30.29 ± 0.27 
Penk 24.96 ± 0.25 25.03 ± 0.51 26.00 ± 0.26 25.85 ± 0.15 
Pspn 30.85 ± 0.19 30.69 ± 0.57 29.18 ± 0.55 30.89 ± 0.62 
Tac1 29.61 ± 0.08 30.08 ± 0.85 29.89 ± 0.30 29.42 ± 0.22 
Tacr1 31.61 ± 0.22 30.94 ± 0.62 31.68 ± 0.61 31.01 ± 0.28 
 
*n=5 for PMX, n=3 for sham surgery.  523 
